Literature DB >> 12550002

[Identification of factors responsible for oral over-anticoagulation in outpatients with heart disease].

Román Freixa1, Pedro Blanch, Montse Ibernón, Jaume Padró, Javier Delso, José Luis Sobrepera, Elena Salas, Laura Dos, Pere Codinach.   

Abstract

BACKGROUND: Few studies have attempted to investigate the clinical course or identify factors responsible for excessive anticoagulation in patients with heart disease.
OBJECTIVES: To determine the incidence of excessive anticoagulation in outpatients with heart disease treated with acenocoumarol, analyze the factors related with over-anticoagulation, and identify bleeding complications. PATIENTS AND
METHOD: This 7-month prospective observational study included consecutive outpatients anticoagulated with acenocoumarol. They were seen in an anticoagulation unit. The high INR group of 55 over-anticoagulated patients had at least one test with INR > 5. The control group of 49 patients had INR results strictly within therapeutic range.
RESULTS: A total of 3,683 INR determinations were made in 512 patients. Seventy-seven tests had an INR > 5 (a 2% overall incidence of high-INR). In the group of 55 INR < 5 patients, 31% had more than one INR determination > 5 during follow-up. Multivariate analysis identified four variables as independent predictors of over-anticoagulation: artificial heart valve, poor treatment compliance, addition of potentially interactive new drugs, and illness in the last month. The high-INR group patients had more bleeding episodes (21.8 vs 4.08%; p = 0.008), one of which was major.
CONCLUSION: The incidence of excessive oral anticoagulation in our outpatient population was similar to that reported in other studies. Patients with INR > 5 had more total bleeding complications, mostly minor. It is recommended to proceed carefully with oral anticoagulant therapy in patients with an artificial heart valve, suspected poor treatment compliance, addition of potentially interactive new drugs, and illness in the last month.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12550002     DOI: 10.1016/s0300-8932(03)76823-7

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  1 in total

1.  Oral anticoagulant treatment: risk factors involved in 500 intracranial hemorrhages.

Authors:  A Cantalapiedra; O Gutierrez; J I Tortosa; M Yañez; M Dueñas; E Fernandez Fontecha; M J Peñarrubia; L J García-Frade
Journal:  J Thromb Thrombolysis       Date:  2006-10       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.